Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
Key Financial Performance
Revenue Q4 2024 $1.6 billion, up 8.3% underlying growth (7.8% reported growth) year-over-year, driven by strong December performance and two additional trading days.
Revenue Full Year 2024 $5.8 billion, up 5.3% underlying growth (4.7% reported growth) year-over-year, with all segments contributing significantly.
Gross Profit $4.09 billion with a gross margin of 70.3%, down 40 basis points year-over-year due to price impacts from joint repair VBP in China.
Trading Profit $1.05 billion, up 8.2% year-over-year, with trading margin expansion of 60 basis points to 18.1%.
Adjusted Earnings Per Share $0.843, up 1.7% year-over-year, impacted by higher tax and interest expenses.
IFRS Earnings Per Share $0.472, grew significantly due to lower restructuring charges and costs from the completed EU MDR program.
Free Cash Flow $551 million, improved due to lower restructuring costs and better cash generation.
Net Debt $2.7 billion, decreased by $67 million year-over-year.
Cash Conversion Rate 95%, ahead of target and significantly improved from 65% in 2023.
Return on Invested Capital (ROIC) 7.4%, improved by 150 basis points year-over-year, with expectations to exceed cost of capital in 2025.
Trading Margin Expansion 60 basis points year-over-year, driven by operational savings and revenue leverage.
Cost Savings from 12-Point Plan Total gross cost savings expected between $325 million and $375 million, with annualized benefits of $239 million.
Headcount Reduction 9% overall reduction, contributing to operational savings.
Inventory Days 507 days, improved by 23 days year-over-year.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Product Launches: In 2024, over 60% of revenue growth came from products launched in the last five years, with significant contributions from CORI and AETOS shoulder.
Innovation in Existing Products: CORI has added 10 new features since 2022, and Regeneten has received 510(k) clearance for use in extra-articular ligament repair.
New Platforms: AETOS Shoulder and CATALYSTEM were launched, with plans for a stemless implant in 2025.
Digital Capabilities: Next-generation digital products are being developed, including video-based navigation for arthroscopic procedures.
IM Nails Development: New generation IM nails for trauma are in development, targeting a $1.3 billion global market.
Market Growth: Overall revenue growth for 2024 was 5.3%, with expectations of around 5% growth for 2025.
US Market Performance: US recon business showed 11.9% growth in Q4, with expectations for continued improvement.
China Market Challenges: China posed a 280 basis point headwind to group growth in Q4, with ongoing challenges expected in 2025.
Cost Savings: Total gross cost savings are expected to be between $325 million and $375 million, with significant savings from manufacturing and procurement.
Headcount Reduction: Headcount reduced by around 9% overall, with further reductions expected in 2025.
Cash Generation: Free cash flow improved to $551 million in 2024, with expectations to exceed $600 million in 2025.
12-Point Plan: The 12-Point Plan has been fully embedded, driving operational improvements and accountability across the organization.
Organizational Restructuring: Transitioned to a global business unit model to enhance accountability and commercial execution.
Future Outlook: Expect continued margin expansion in 2025 and beyond, with a trading margin target of 19% to 20%.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
China Market Headwinds: China cost 280 basis points of group growth in Q4, with continued headwinds expected in 2025 due to VBP pricing impacting both Orthopedics and Sports Medicine.
Supply Chain Challenges: Significant supply chain challenges were noted, particularly affecting the recon business, which took time to improve.
Inflation and Cost Pressures: The company faced almost 700 basis points of headwinds from inflation and other external factors, which impacted profitability despite revenue growth.
Regulatory Issues: The implementation of VBP pricing in China is expected to create a sales headwind of around $25 million in 2025.
Operational Changes and Restructuring: The company has reduced its headcount by around 9% and closed four orthopedic facilities, which may impact operational capacity in the short term.
Economic Factors: The overall economic environment, including inflation and market conditions, has posed challenges that the company has had to navigate.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
12-Point Plan: The 12-Point Plan is delivering financial outcomes, with operational and commercial actions leading to higher growth and margin expansion.
Cost Savings: Total gross cost savings are expected to be between $325 million and $375 million, with a focus on manufacturing and procurement.
Global Business Unit Model: Transition to a global business unit model to enhance accountability and commercial execution.
Innovation: Over 60% of revenue growth in 2024 came from products launched in the last five years, indicating a strong innovation pipeline.
Revenue Growth: Expecting revenue growth of around 5% for 2025.
Trading Margin: Guidance for trading margin expansion to between 19% and 20% in 2025.
Free Cash Flow: Expected improvement in free cash flow to over $600 million in 2025.
Return on Invested Capital (ROIC): ROIC expected to return above cost of capital in 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Full Year Dividend: The proposed full year dividend is unchanged at $0.375 per share.
Cost Savings from 12-Point Plan: Total gross cost savings are now expected to be between $325 million and $375 million.
Share Buyback Consideration: The financial return on share buybacks is a relevant hurdle for M&A.
Free Cash Flow: Free cash flow improved to $551 million, with expectations to exceed $600 million in 2025.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What gives you the confidence that orthopedics is going to recover towards the end of Q1, and how much visibility do you have into end market demand?
A:We expect Q1 to be the low watermark in terms of inventories coming down to equilibrate. We have committed volumes for tenders at a known price, and we expect some recovery in the second half of the year.
Q:Are you seeing volumes tick up in sports as you had previously expected?
A:In the first half of the year, we expect sports VBP on joint repair to play through, with adjustments in the channel leading up to that.
Q:What gives you confidence that the U.S. hips and knees market will grow in line with the market by the end of 2025?
A:Confidence comes from executing multiple elements of our transformation program, improving supply, and commercial execution, which has led to a more stable account base.
Q:Can you reassure us that R&D is not being used to manage margins?
A:Innovation is key to our growth, and we have not cut any programs. R&D looks down year-on-year due to one-time effects, but we are adding programs and funding innovation.
Q:Can you discuss your effort to reduce SKUs in hips and knees?
A:SKU reduction is part of our plan, but it's not the biggest lever for margin expansion. We've made good progress, especially in Asia.
Q:Can you give us a bridge on margin improvement in Orthopedics?
A:We expect at least a 200 bps increase in Orthopedics margin, driven by operational leverage and savings from manufacturing closures.
Q:What is the status of your headcount reduction program?
A:Most reductions come from factory closures in Orthopedics, and we've made significant SG&A-related headcount savings.
Q:What are your expectations for pricing in major markets?
A:Historically, we expect 1% to 2% price erosion, but we have been flat to slightly positive recently due to passing through inflation-related costs.
Q:What are the levers that might leave you at the bottom or top end of your guidance range?
A:The range is influenced by uncertainty around China, operational leverage, and cost savings.
Q:What is your outlook for inventory reduction and free cash flow?
A:We aim for free cash flow north of $600 million, with improvements in inventory quality and DSI.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific targets for inventory reduction and the exact impact of tariffs on different parts of the business. Additionally, there was a lack of clarity on the competitive dynamics in the Chinese market and the potential go/no-go decision for the Orthopedics business.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AET
AWM
Capital
China VBP
DSI
Deepak
Point Plan
RD
ROIC
Recon
Slide
Sports Medicine
Wound
accountability
allocation
approach
base
business
cash flow
charge
customer
efficiency
financials
finish
generation
headcount
headwind basis
inflation leverage
interim
leverage cost
margin basis
orthopedics
point headwind
point margin
point plan
priority
profitability
rate
recon robotics
reduction
restructuring
shoulder
spend
trading day
trading statement
wave
SNN Transcript
Smith & Nephew plc (SNN) Q4 2025 Earnings Call Transcript
Positive3-2
The earnings call highlighted strong financial performance with a 21% EPS increase and a $500 million share buyback. Trading margins expanded, and ROIC improved. Product updates like the CORI Shoulder platform and REGENETEN's market potential were promising. Despite some uncertainties in China and the skin substitutes market, the company maintains a positive outlook for 2026 with growth in key areas. The Q&A reflected confidence in strategic initiatives and competitive positioning, supporting a positive sentiment.
Smith & Nephew plc (SNN) Q2 2025 Earnings Call Transcript
Unknown8-5
The earnings call summary presents a mixed outlook: strong product innovation and market strategy are offset by uncertainties in tariffs and CMS proposals. The Q&A session reveals management's cautious optimism, but with some unclear responses. Financial performance and guidance remain stable, yet the lack of clear answers on certain risks tempers enthusiasm. Given these factors, a neutral rating is appropriate as the stock may not significantly change over the next two weeks.
Smith & Nephew plc (SNN) Q1 2025 Earnings Call Transcript
Unknown5-2
The earnings call presents a mixed picture: moderate revenue growth, strong performance in specific segments, and effective tariff mitigation strategies, but also challenges like headwinds in China and lack of share buybacks. The Q&A reveals optimism about future growth and margin improvements, but some concerns remain unaddressed. The absence of a share buyback program and the challenges in emerging markets balance the positives, leading to a neutral stock price prediction over the next two weeks.
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Unknown2-25
The earnings call presents a mixed picture. Financial performance shows growth in revenue and trading profit, but gross margins have declined slightly. The unchanged dividend and improved free cash flow are positive, while headcount reductions and cost savings indicate efficiency efforts. However, management's unclear responses in the Q&A, particularly regarding inventory reduction and competitive dynamics in China, suggest some uncertainty. The overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
SNN Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
